WAVE LIFE SCIENCES LTD (WVE)

Company Profile

Wave Life Sciences Ltd. is a clinical-stage genetic medicines company, which engages in the development of proprietary synthetic chemistry drug. The company employs 250 full-time employees The company went IPO on 2015-11-11. The firm is engaged in developing medicines across multiple therapeutic modalities using PRISM, its proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. The Company’s ribonucleic acid (RNA)-targeting oligonucleotides is designed to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. Its lead programs are designed to treat genetic diseases, including those in muscle, including Duchenne muscular dystrophy (DMD); liver, including alpha-1 antitrypsin deficiency (AATD); and the central nervous system (CNS), including Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These programs include WVE-N531, WVE-006, WVE-003, and WVE-004.

Company Info

WAVE LIFE SCIENCES LTD

7 Straits View, #12-00, Marina One East Tower

Singapore 018936

P: 6562363388

CEO: Paul B. Bolno

Employees: 250

Website: https://www.wavelifesciences.com/